SLC2A1 and neoplasm: By targeting enzymes such as LDHA, GLUT1, HK2, PKM2, GLS1/2, FASN, ACLY and ACC, researchers have demonstrated the feasibility of disrupting tumor bioenergetics and biosynthetic machinery.